Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

This study has been completed.
Sponsor:
Information provided by:
BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00035022
First received: May 2, 2002
Last updated: January 12, 2006
Last verified: February 2005

May 2, 2002
January 12, 2006
August 2001
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00035022 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies

The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.

Despite the great strides that have been made in improving the outcome with frontline programs of intensive chemotherapy in patients with aggressive T-cell malignancies, the prognosis with relapsed or refractory T-cell leukemias or lymphomas is poor. BCX-1777 is a purine nucleoside phosphorylase (PNP) inhibitor and a potential T-cell target therapy.

The purpose of the phase I portion of the study is to determine the maximum tolerated dose (MTD) of BCX-1777 and the dose to be studied in the phase II portion of the study.

The purpose of the phase II portion of the study is to determine the safety and efficacy of BCX-1777 in patients with relapsed or refractory aggressive T-cell malignancies.

Patients who respond to BCX-1777 or have stable disease may be eligible to receive an additional course of treatment.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia, Lymphocytic
  • Lymphoma
Drug: BCX-1777
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
71
March 2004
Not Provided

Inclusion Criteria:

  • Previously treated, relapsed or refractory aggressive T-cell malignancies (leukemias and lymphomas) histologically proven with measurable disease.
  • Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
  • All ages are eligible. Pediatric patients (<15 years of age) are eligible to be treated at a dose level previously tested in adults.
  • Adequate liver and renal function.
  • Patients with prior history of stem cell transplant if they meet all other eligibility requirements.
  • Negative pregnancy test within 72 hours of study treatment in females of childbearing potential.
  • Life expectancy of at least 2 months.

Exclusion:

  • Active serious infection not controlled by oral or intravenous antibiotics.
  • Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side-effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.
  • Concurrent treatment with other anti-cancer agents.
  • Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy. Lumbar puncture not required in asymptomatic patients.
  • Pregnant and/or lactating women; or fertile men or women not willing to use contraception.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00035022
BC-01-02
Not Provided
Not Provided
BioCryst Pharmaceuticals
Not Provided
Principal Investigator: Deborah A. Thomas, M.D. M.D. Anderson Cancer Center
BioCryst Pharmaceuticals
February 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP